Vaccines against SARS-CoV-2 are urgently required, but early development of vaccines against SARS-CoV-1 resulted in enhanced disease after vaccination. Careful assessment of this phenomena is warranted for vaccine development against SARS CoV-2. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent high dose challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titre were boosted by a second dose. Data from these challenge models on the absence of enhanced disease and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Lambe T, Spencer A J, Thomas K M, Gooch K E, Thomas S, White A D, Humphries H E, Wright D, Belij-Rammerstorfer S, Thakur N, Conceicao C, Watson R, Alden L, Allen L, Aram M, Bewley K R, Brunt E, Brown P, Cavell B E, Cobb R, Fotheringham S A, Gilbride C, Harris D J, Ho C M K, Hunter L, Kennard C L, Leung S, Lucas V, Ngabo D, Ryan K A, Sharpe H, Sarfas C, Sibley L, Slack G S, Ulaszewska M, Wand N, Wiblin N R, Gleeson F V, Bailey D, Sharpe S, Charlton S, Salguero F J, Carroll M W, Gilbert S C
Citation: Communications Biology 4 (4), 915